Concretely: dulaglutide · fourteen days.
This is a procedural question rather than a theoretical one, and I would like the procedure rather than the theory.
What I have done so far is read the label documentation where it exists and the two pharmacopoeial monographs that are publicly available, which cover the licensed presentation and say nothing about a research one.
What does a defensible version of this look like in practice?
14 days past a due dose is 2 half-lives at the seven-day half-life this class runs on, which leaves about 25 per cent of that dose still circulating. One line of arithmetic: remaining fraction is one half raised to days over half-life, so 0.5^(14÷7) = 0.25. At 25 per cent you have not been off it in any meaningful sense. The interval stretched from 7 days to 21 and the trough went lower than usual; that is the whole of what happened. What the product label says and what the pharmacokinetics say are two different answers here, and the first is the one that governs. Restarting, holding or stepping down after a gap is decided under supervision, and nothing here is medical advice.
Start with the interval since the missed dose, because that single number determines the answer.
The published guidance for the weekly agents is broadly: if the missed dose is remembered within about five days, take it and continue on the usual day; if more than five days have passed, skip it and take the next scheduled dose.
| Agent | Start | Step interval | Maintenance range | Max studied |
|---|---|---|---|---|
| Semaglutide (weight management) | 0.25 mg/wk | 4 weeks | 1.7–2.4 mg/wk | 2.4 mg/wk |
| Semaglutide (T2DM) | 0.25 mg/wk | 4 weeks | 0.5–2.0 mg/wk | 2.0 mg/wk |
| Tirzepatide | 2.5 mg/wk | 4 weeks | 5–15 mg/wk | 15 mg/wk |
| Liraglutide (weight management) | 0.6 mg/day | 1 week | 3.0 mg/day | 3.0 mg/day |
| Oral semaglutide | 3 mg/day | 4 weeks | 7–14 mg/day | 50 mg/day (trial) |
Structure is identical across the class: small start, four-week steps, a defined maintenance range, a defined ceiling.
To change your regular dosing day, move the next dose later rather than earlier, keeping at least three days between doses for a weekly agent. Moving earlier compresses the interval and raises exposure.
Peak exposure rather than average exposure drives gastrointestinal tolerability, which is the reason doubling up is advised against.
Repeated missed doses are a different problem from an occasional one and should be treated as such.
Never double up. Peak exposure is what drives the symptoms.
Analytical standards and reagents with traceable certificates. Every quantitative result you read inherits the accuracy of the standard behind it.
Shop standardsThis is one of the questions where the pharmacokinetics gives a reassuring answer and the anxiety persists anyway.
Never take two doses close together to compensate. The peak exposure is roughly doubled, and gastrointestinal tolerability tracks peak exposure closely.
The part that matters: for a daily agent with a thirteen-hour half-life, a missed dose is a much larger proportional loss. The usual approach is to skip it and take the next scheduled one rather than doubling.
Half-lives across the class span roughly thirteen hours to one week, which is why the answer is agent-specific.
The caveat is that anyone on other glucose-lowering medication has an interaction question here that needs a prescriber.
Two or more missed weekly doses means considering a lower restarting step.
edited 26 Sept 2025 by lucia_marchetti — updated for the 2026 guidance change
Answering this needs the agent, since the answer for a thirteen-hour half-life and a one-week half-life are entirely different.
One missed dose is not a reason to change the schedule or the dose. Two or more is a reason to consider where you are restarting from.
With a one-week half-life dosed weekly, missing one dose means exposure falls by about half over the following week — the same trough you would reach if you simply extended the interval. That is well within the range the agent operates in.
Nothing here is medical advice, and research-use compounds are not approved for human use.
To move your dosing day, move it later and keep three days between doses.
Answer first: it depends on the half-life and on how long ago the dose was due, and for a weekly agent the tolerance is much wider than people fear.
If more than two consecutive weekly doses are missed, tolerance to the gastrointestinal effects begins to fade and re-titration from a lower step becomes the sensible approach.
Loss of tolerance during a treatment gap is documented and is the basis for re-titration after an interruption.
Set a recurring reminder attached to something you already do weekly.
The short version: for a weekly agent, take it if you are within a few days; if you are close to the next scheduled dose, skip it and resume.
Set a recurring reminder tied to something you already do weekly. The commonest cause of a missed dose is not forgetting the drug but losing track of the day.
A published missed-dose window applies to a licensed product with a known content, which unverified material is not.
Within about five days for a weekly agent, take it. Beyond that, skip and resume.
edited 22 Jan 2026 by leonid_marchuk — added the placebo-arm figures
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.